A Study of Cytotoxic T Lymphocyte (CTL) Therapy in HIV-Infected Patients
Status:
Terminated
Trial end date:
2005-06-01
Target enrollment:
Participant gender:
Summary
To define the safety of cytotoxic T lymphocytes (CTLs) generated from sibling-supplied
dendritic cells and lymphocytes and infused into an HIV-infected patient. To determine the
efficacy of these CTLs in helping the immune system to fight HIV.
With lower CD4 counts, HIV-infected patients may not be able to produce dendritic cells and
lymphocytes, special types of immune cells that generate HIV-specific CTLs. Infusion of CTLs
generated from the dendritic cells and lymphocytes of an HIV-negative sibling may enable the
body to recognize HIV more readily and increase immune response against the virus.
Phase:
N/A
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)